Amendment: SEC Form SC 13G/A filed by Harrow Inc.
$HROW
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/11/2025 | $76.00 | Overweight | Cantor Fitzgerald |
| 6/12/2025 | $62.00 | Buy | BTIG Research |
| 6/10/2025 | Outperform | William Blair | |
| 2/6/2025 | $57.00 | Buy | H.C. Wainwright |
| 12/4/2024 | $73.00 → $69.00 | Buy | B. Riley Securities |
| 4/11/2024 | $24.00 | Buy | Craig Hallum |
| 9/8/2022 | $17.00 | Buy | B. Riley Securities |
| 10/14/2021 | $16.00 | Buy | B. Riley Securities |
Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter "Samsung Bioepis") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases. BYOOVIZ has been commercialized
Harrow will assume full commercial responsibility for BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) upon full transition of Biogen's commercialization rights back to Samsung Bioepis by the end of 2025 BYOOVIZ, approved by the FDA in September 2021 as the first ophthalmology biosimilar in the US, has been commercially available since June 2022 OPUVIZ was approved by the FDA in May 2024 Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (NASDAQ:HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUC
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00
BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00
William Blair initiated coverage of Harrow with a rating of Outperform
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
8-K - HARROW, INC. (0001360214) (Filer)
S-8 - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin
First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th